Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Seirogan Quick C is an oral antidiarrheal medication developed by Taiko Pharmaceutical, featuring wood creosote as its sole active ingredient. Unlike the traditional Seirogan pill formulation, which contains multiple botanical extracts, Quick C is delivered in a liquid-filled soft capsule designed for rapid dissolution and faster onset of action. Wood creosote, a mixture of phenolic compounds derived from wood tar, exerts its therapeutic effect by normalizing intestinal water metabolism—specifically by inhibiting excess fluid secretion and promoting absorption—and by regulating intestinal motility without suppressing natural peristalsis. It is widely used in Japan as an over-the-counter treatment for diarrhea, food poisoning, and water-induced distress. Clinical research, including the jRCTs041220146 trial, is currently evaluating its efficacy in managing metformin-induced gastrointestinal side effects, such as diarrhea, in patients with type 2 diabetes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Seirogan Quick C.